Immunohistochemical study of XXXX , @entity5091 and @entity5089 in @entity14 and review of literature.

@entity5 @entity5091 @entity5089 @entity14 @entity2355
BACKGROUND: A hallmark of @entity14 is their ability to secrete mucus. Aberrant expression of mucins and alterations in their glycosylation are associated with the development and progression of @entity5 . Therefore, mucins can be used as markers of @entity5 . @entity5 -associated mucins are also used as immunotargets in the treatment of @entity5 . The present work aimed to study the patterns of expression of @entity2355 , @entity5091 and @entity5089 in @entity14 using immunohistochemistry and their relationship with site, histological differentiation and stage. METHODS: Fifty cases of @entity14 were chosen for the study. The histopathology slides were reviewed and blocks were retrieved. Using manual method, tissue microarray blocks were prepared. Immunostaining for @entity2355 , @entity5091 and @entity5089 was performed on slides cut from the tissue microarray block. RESULTS: We found that @entity2355 expression was upregulated to 39  %, @entity5091 expression was downregulated to 43  % and @entity5089 was aberrantly expressed in 24  % of @entity14 ( @entity14 ). There was a significant correlation between @entity2355 positivity and @entity5 differentiation. As the grade increased from well to moderately differentiated, @entity2355 expression increased from 1   1 % to 55  % (p-value 0.01). There was a statistically significant difference between @entity5089 positivity and grade of @entity5 (p-value 0.006). The percentage of cases showing @entity5089 expression increased as the stage of disease progressed from 1 to 4. However, there was no significant difference in @entity5089 positivity and stage of @entity14 (p-value 0.77). CONCLUSION: We do not find any correlation between @entity5 stage or site and @entity2355 , @entity5091 or @entity5089 expression. @entity2355 and @entity5089 expression showed significant correlation with @entity5 grade.
